Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma
Public ClinicalTrials.gov record NCT02537548. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma With Isolated Retroperitoneal Disease (1-3cm)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial studies how well retroperitoneal lymph node dissection (RPLND) works in treating patients with stage I-IIa testicular seminoma. The retroperitoneum is the space in the body behind the intestines that is typically the first place that seminoma spreads. RPLND is a surgery that removes lymph nodes in this area to treat testicular seminoma and may experience fewer long-term toxicities, such as a second cancer, cardiovascular disease, metabolic syndrome (pre-diabetes), or lung disease.
Study identification
- NCT ID
- NCT02537548
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 55 participants
Conditions and interventions
Interventions
- Laboratory Biomarker Analysis Other
- Retroperitoneal Lymph Node Dissection Procedure
Other · Procedure
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 28, 2015 (Actual)
- Primary completion
- Dec 31, 2026 (Estimated)
- Completion
- Dec 31, 2027 (Estimated)
- Last update posted
- Jun 9, 2026
2015 – 2027
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Loma Linda University Medical Center | Loma Linda | California | 92350 | — |
| USC / Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| University of California, San Francisco | San Francisco | California | 94143 | — |
| Stanford University Hospitals & Clinics | Stanford | California | 94305 | — |
| University of Colorado Hospital - Aurora | Aurora | Colorado | 80045 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland | 21205 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903-2681 | — |
| Stephenson Cancer Center, University of Oklahoma | Oklahoma City | Oklahoma | 73104 | — |
| UTSouthwestern Medical Center | Dallas | Texas | 75390-9110 | — |
| Madigan Army Medical Center | Tacoma | Washington | 98431 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02537548, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 9, 2026 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02537548 live on ClinicalTrials.gov.